Karolinska Development publishes Interim Report (January - September 2017) and reports a positive result for the third quarter


STOCKHOLM - October 31, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for January - September 2017. This is the first time since 2014, when Karolinska Development implemented its new strategy, that the company reports a positive quarterly result. The company will host a conference call and an online presentation on October 31, at 2 pm CET - details below. The full report is available on the Company's website.

"It is gratifying that Karolinska Development is starting to see the effects of the strategy shift implemented in 2014. We have posted a positive quarterly result and our portfolio companies are well-positioned to exploit the phase II results that are expected to become available in 2018. The past quarter has seen the value of Karolinska Development's portfolio increase by SEK 229 million, primarily due to the positive results of Umecrine Cognition's phase Ib study and the stock market listing of Xspray Pharma", says Viktor Drvota, CEO, Karolinska Development.

Third Quarter Highlights 2017

  • Karolinska Development posted a positive quarterly result for the first time since the company's strategy shift in 2014.
  • Karolinska Development reports an increase in the value of its holdings in Umecrine Cognition as a result of the company's positive phase Ib-data (October 2017).
  • Umecrine Cognition presented positive phase Ib data for its GR3027 candidate drug, which is being developed for the treatment of hepatic encephalopathy (September 2017).
  • BioArctic announced that it intends to float the company's class B shares on the NASDAQ First North Stockholm exchange (September 2017).
  • Xspray Pharma AB was listed on the NASDAQ First North exchange in Stockholm. When Karolinska Development sold its Xspray holding to new owners in September 2015, an earn-out agreement ensured that it would, in conjunction with a stock market listing, be entitled to receive a holding of 3.74% of the number of shares after the flotation. Based on the share price on 30 September 2017, the value of these shares and the shares owned indirectly via KCIF Co-Investment Fund KB corresponds to SEK 16.2 million, and the value of Karolinska Development's portfolio holdings has, therefore, increased by an equivalent amount (September 2017). 
  • Aprea Therapeutics enrolled the first patient in a phase Ib/II study of the APR-246 candidate drug for patients with platinum-resistant, high-grade serous ovarian cancer (HGSOC) (August 2017).
  • Karolinska Development appointed Fredrik Järrsten to the position of CFO. Fredrik Järrsten will take up his new position in late 2017, succeeding Christian Tange who, after four years at Karolinska Development, is leaving the company to pursue other opportunities. Tange will, however, remain with the company for a period of time after Järrsten takes over as CFO, in order to ensure an orderly handover (August 2017). 

Significant events after the end of Q3 2017

  • Aprea Therapeutics received the last tranche of SEK 188 million in a financing round of totally SEK 437 million from 2016. Aprea also announced the enrollment of the first patient in a phase Ib/II study in esophageal cancer (October 2017).
  • Umecrine Cognition announced that it had secured SEK 20 million in financing for an exploratory, phase IIa study of the company's candidate drug, GR3027, in an additional therapeutic indication area, namely idiopathic hypersomnia (October 2017).
  • BioArctic was listed on the NASDAQ First North exchange. Karolinska Development's holding are valued at SEK 48 million, based on the offering price on 12 October, corresponding to a sum that is 80 times the investment (October 2017).

  • Karolinska Development and KCIF Co-Investment Fund KB announced the divestment of their holdings in Xspray Pharma AB. The transaction generated SEK 13.3 million to Karolinska Development (October 2017).

Financial update

  • Karolinska Development posted a positive quarterly result for the first time since the company's strategy shift in 2014. The net profit totalled SEK 194.1 million (net loss of SEK 17.9 million in Q3 2016), and the earnings per share were SEK 3.0 (SEK -0.3 in Q3 2016).
  • The result of change in portfolio fair value amounted to SEK 212.2 million. The increase was primarily due to the increase in the valuation of the Umecrine Cognition holding due to the positive results from the phase Ib study presented during the quarter, and to the flotation of Xspray Pharma.
  • The total fair value of the portfolio was SEK 674.0 million at the end of September 2017, an increase from SEK 445.0 million at the end of June 2017.
  • Net sales totalled SEK 0.5 million during the third quarter 2017 (SEK 0.4 million in Q3 2016). 
  • Karolinska Development invested a total of SEK 17.1 million in its portfolio companies during the third quarter. Third quarter investments in the portfolio companies by Karolinska Development and other specialised life sciences investors totalled SEK 21.4 million. 
  • Cash and cash equivalents decreased by SEK 23.7 million during the third quarter, totalling SEK 165.4 million on 30 September 2017.
  • The Parent Company's equity at the end of September 2017 was SEK 235.1 million.

Conference Call and Webbcast

The Company will host a conference call on October 31, 2017 at 2 pm CET. Please dial in at one of the following numbers a few minutes before the start of the conference call:

From Sweden: +46 (0) 8 505 564 74
From the US: +1 855 753 22 30
From the UK: +44 (0) 20 336 453 74

The presentation will also be webcast and can be accessed from the following web address:

Host: Viktor Drvota, CEO.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail:


About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 08:00 am CET on 31 October 2017.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire




Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Inspiration Mining to File a Complaint with OSC Against Stockwatch20.2.2018 21:35Pressmeddelande

TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation (the Corporation) (CSE:ISM) reports that Stockwatch, a Vancouver based news service, has published incorrect news. Inspiration intends to initiate a one (1) for two (2) FORWARD SPLIT. Inspiration fully intends to bring forth a resolution at its upcoming Annual General Meeting to initiate a FORWARD SPLIT, on a one (1) old share for two (2) new share basis. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements based on assumptions, uncertainties and management's best estimates of future events. Actual results may differ materially from those currently anticipated. Investors are cautioned that such forward-looking statements involve risks and uncertainties. Important

Aurora Releases Third Quarter Results20.2.2018 21:08Pressmeddelande

Aurora Solar Technologies Inc. / Aurora Releases Third Quarter Results . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. NORTH VANCOUVER, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora")("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82), a leader in inline measurement and control technology for the photovoltaic manufacturing industry, released today its third quarter results. Revenue for the quarter was $337,325, gross margin was 62.9%, resulting in an operating income loss of ($398,959). Year-to-date for nine months, the Company has recognized $1,903,020 in revenue, an increase of 238% over the same period last year. The operating income (loss) year to date was ($674,983), a reduction of 67.7% from the same period last fiscal year. The Company also confirms, excluding new potential orders, that it has unrecognized revenue from shipments and order backlog of approxi

Bermuda Principles event merges science and business20.2.2018 16:36Pressmeddelande

HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research. Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa. Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors. "I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to p

Globecomm Joins Amazon Web Services Partner Network20.2.2018 16:00Pressmeddelande

Highlights Globecomm establishes direct access to Amazon Web Services (AWS) Direct Connect at key datacenter locations. Customers in U.S. Government, media and entertainment, enterprise video and the Internet of Things (IoT) can interoperate cloud-based services with Globecomm's global satellite and fiber network to reduce capital expenditure and ramp up networks and services faster. Globecomm's suite of Software-as-a-Service (SaaS) applications run on AWS, accessible across both AWS and Globecomm's global network. Globecomm's team in place to design, develop and deliver cloud-centric as well as hybrid architectures for end-to-end services and customer solutions. HAUPPAUGE, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Globecomm announced today that it has joined the Amazon Web Services (AWS) Partner Network (APN) as a Standard Technology Partner. This agreement will enable Globecomm to seamlessly interoperate its global satellite and fiber network with AWS's storage, compute and cloud conte

Elite Capital & Co. awarded Infrastructure Project Finance Provider 2018 by New European Economy20.2.2018 15:41Pressmeddelande

LONDON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The Information Department at Elite Capital & Co. Limited (ECC), announced today that the company features in the specialized and prestigious New European Economy Magazine in its January 2018 issue in Britain and the European Union countries as the "Infrastructure Project Finance Provider 2018". The award is the result of focused efforts and synergy between the ECC Board of Directors and our employees and strategic partners all over the world over the past years. It also reflects the ability of the Company's strategy to adapt to the prevailing global economic circumstances and testifies to the viability of the planning process adopted by the Board of Directors. Dr. Faisal Khazaal, Chairman of Elite Capital & Co. commented on the occasion, "I should thank Mr. George Matharu, President of ECC and his Board Members who make ceaseless efforts towards ensuring that ECC continues to occupy a prestigious position in the field of finance and economy in

New MindManager 11 for Mac: Visually Capture, Organize, and Share Information to Drive Project and Business Success20.2.2018 15:26Pressmeddelande

Powerful mind mapping and information visualization software introduces its most robust Mac version yet; complete with new diagram types, an expanded template library, advanced mapping capabilities, and improved sharing options OTTAWA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Introduced today, MindManager® 11 for Mac brings new elegance and efficiency to the way individuals and teams organize ideas, tackle tasks, and achieve their goals. Already a leader in mind mapping and information visualization on the Mac, MindManager's new release offers advanced mapping capabilities, new diagram types and templates, and easy ways to share and publish your work - all delivered within a redesigned interface optimized to enhance productivity. Individuals, small businesses, and global organizations rely upon MindManager to efficiently brainstorm and organize ideas, communicate knowledge effectively, and execute project success. MindManager enables users to turn unstructured ideas and information into dynam

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum